26325-21-3

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL-BENZOFURAN-7-YLAMINE is used as a key intermediate in the synthesis of new drugs and pharmaceutical products due to its unique structure and functional groups, which contribute to the development of biologically active molecules and potential drug candidates.
Used in Organic Synthesis:
2-METHYL-BENZOFURAN-7-YLAMINE is used as a valuable building block in organic synthesis, enabling the creation of a variety of biologically active molecules, given its unique structure and reactivity.
Used in Medicinal Chemistry Research:
2-METHYL-BENZOFURAN-7-YLAMINE is utilized as an important target in medicinal chemistry research, where its properties and reactivity are explored to advance the understanding of its potential applications in drug discovery and development.

InChI:InChI=1/C9H9NO/c1-6-5-7-3-2-4-8(10)9(7)11-6/h2-5H,10H2,1H3

Upstream product

• 13680-09-6 2-methyl-7-nitrobenzofuran 
• 88-75-5 2-hydroxynitrobenzene 
• 13350-09-9 1-nitro-2-(prop-2-yn-1-yloxy)benzene 
• 1185300-60-0 2-methyl-benzofuran-7-ylamine hydrochloride 

Downstream Products

• 1400637-53-7 C₂₀H₂₀FNO₄ 
• 1400637-66-2 C₂₀H₂₀⁽¹⁸⁾FNO₄ 
• 1400637-79-7 C₂₀H₂₀BrNO₄ 
• 1400637-94-6 C₁₈H₁₉NO₃ 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES AS RENIN INHIBITORS

A compound of formula (I), formula (I) or pharmaceutically acceptable salt thereof, as renin inhibitor, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of card

Exploration of the structure-activity relationship of the diaryl anilide class of ligands for translocator protein - Potential novel positron emitting tomography imaging agents

A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

7-(N-substituted)amino-2,3-polymethylene benzofurane derivatives with tracheal relaxant activity

A set of twelve 7-(N-substituted)amino-2,3-polymethylenebenzofuranes (1-12) together with three related compounds (13-15) was prepared. Ten selected compounds were tested for tracheal relaxant activity in vitro and two of them (6,7) were also subjected to a broad pharmacological screening. Five compounds (2, 7, 9, 12, 14) at the concentration of 30 μg/ml exhibited high tracheal relaxant activity (73-94% tone reduction) that was superior than that of theophylline at the same concentration. The 7-(N-trifluoromethylsulfonyl)amino-2,3-tetramethylenebenzofurane (9) was highly active till the concentration of 1 μg/ml giving a stronger tracheal relaxation than amrinone at 3 μg/ml. On the other hand the general screening did not show any other major activity. The benzofurane derivatives 1-13 were obtained through obvious steps from the corresponding 7-nitrobenzofuranes, which were prepared by a Fischer indole-like cyclization of O-[(2-nitro)phenyl] ketone oximes. In one case two peculiar side products were isolated.